Every 10-Q that GENVOR INC (GNVR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GNVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNVR filings page.
Genvor Incorporated reported another pre-revenue quarter and highlighted serious liquidity risks. For the three months ended March 31, 2026, the company generated no revenue and posted a net loss of $429,567, widening from $298,983 a year earlier. For the six-month period, the net loss was $1,005,847, a sharp improvement from $5,300,234 mainly because prior-year stock-based CEO compensation was much higher.
At March 31, 2026, Genvor held only $94,808 in cash, had a working capital deficit of $891,095 and an accumulated deficit of $27,199,153. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional financings.
During the first half of fiscal 2026, Genvor raised $665,333 through common stock and pre-funded warrant issuances, helping fund operating cash outflows of $594,213. Subsequent to quarter-end, it signed a securities purchase agreement with Evergreen Capital for a convertible note of up to $800,000 and warrants for up to 600,000 shares, and entered a non-binding MOU with Canlab International™ to explore peptide-based products for human health markets.
Genvor Incorporated reported another quarterly loss and highlighted serious liquidity risks while filing an amendment to correct cover-page checkboxes. For the three months ended December 31, 2025, the company generated no revenue and posted a net loss of $576,280, a sharp improvement from $5,001,251 a year earlier as stock-based compensation and overall operating expenses declined.
Cash was $103,580 at December 31, 2025 with a working capital deficit of about $1.06M, and management stated that these conditions raise substantial doubt about Genvor’s ability to continue as a going concern. To fund operations, the company relied on issuing equity for cash, services, debt conversions, and warrant exercises, bringing common shares to 34,434,938 outstanding as of February 11, 2026.
Genvor Incorporated reported another loss-making quarter with no revenue for the three months ended December 31, 2025. The company generated no sales while cutting its net loss to about $576,000 from roughly $5.0 million a year earlier, mainly due to much lower compensation and stock-based expenses.
Cash increased to about $103,580, helped by $260,000 raised from common stock sales, but Genvor still had a working capital deficit of roughly $1.06 million and an accumulated deficit of about $26.8 million. Management disclosed that these recurring losses, negative cash flow and limited cash raise substantial doubt about the company’s ability to continue as a going concern.
The share count continued to rise, reaching 34.43 million common shares outstanding at December 31, 2025, plus significant convertible preferred stock and warrants that could add further dilution. Much of Genvor’s obligations, including salary and advances, are owed to its CEO and scientific advisors, who earn 8% interest and can convert accrued amounts into stock, tying liquidity and dilution closely to related-party arrangements.